• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Neumora Therapeutics Inc.

    3/3/25 4:44:34 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NMRA alert in real time by email
    S-8 1 d931448ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 3, 2025

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Neumora Therapeutics, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   84-4367680

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

    490 Arsenal Way, Suite 200

    Watertown, Massachusetts

      02472
    (Address of Principal Executive Offices)   (Zip Code)

     

     

    2023 Incentive Award Plan

    2023 Employee Stock Purchase Plan

    (Full Title of the Plan)

     

     

    Paul L. Berns

    Chief Executive Officer

    Neumora Therapeutics, Inc.

    490 Arsenal Way, Suite 200

    Watertown, Massachusetts

    (857) 760-0900

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Kathleen M. Wells

    Shayne Kennedy

    Latham & Watkins LLP

    140 Scott Drive

    Menlo Park, California 94025

    (650) 328-4600

     

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

    Proposed sale to take place as soon after the effective date of the

    registration statement as awards under the plans are exercised and/or vest.

     

     

     


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”).

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    In this Registration Statement, Neumora Therapeutics, Inc. is sometimes referred to as “Registrant,” “we,” “us” or “our.”

    REGISTRATION OF ADDITIONAL SECURITIES

    PURSUANT TO GENERAL INSTRUCTION E OF FORM S-8

    This Registration Statement on Form S-8 is filed by the Registrant, relating to (a) 8,085,495 shares of its common stock, $0.0001 par value (the “Common Stock”), issuable to eligible employees, directors and consultants of the Registrant under the Registrant’s 2023 Incentive Award Plan (the “2023 Plan”) and (b) 1,617,099 shares of Common Stock issuable to eligible employees of the Registrant under the Registrant’s 2023 Employee Stock Purchase Plan (the “ESPP”). Shares available for issuance under the 2023 Plan and the ESPP were previously registered on registration statements on Form S-8 filed with the SEC on March 7, 2024, Registration No. 333-277748 and September 20, 2023, Registration No. 333-274593 (together, the “Prior Registration Statements”). The Prior Registration Statements are currently effective. This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with Section E of the General Instructions to Form S-8 regarding Registration of Additional Securities. Pursuant to Section E of the General Instructions to Form S-8, the contents of the Prior Registration Statement are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

    Item 3. Incorporation of Documents by Reference.

    The SEC allows us to incorporate by reference the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this Registration Statement, and later information filed with the SEC will update and supersede this information. We hereby incorporate by reference into this Registration Statement the following documents previously filed with the SEC:

     

      •  

    the contents of the Registrant’s earlier Registration Statements on Form S-8 relating to the 2023 Plan and ESPP, previously filed with the SEC on March 7, 2024 (File No. 333-277748) and September 20, 2023 (File No. 333-274593);

     

      •  

    the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025;

     

      •  

    the Registrant’s Current Reports on Form 8-K filed with the SEC on January  2, 2025 and February 13, 2025 (Item 5.02 only), and Form 8-K/A filed with the SEC on February 21, 2025; and

     

      •  

    the description of the Common Stock contained in the Registrant’s registration statement on Form 8-A (File No. 001-41802), filed by the Registrant with the SEC under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on September 13, 2023, including any amendments or reports filed for the purpose of updating such description.

    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to the registration statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents, except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such


    form that relate to such items, that is not deemed filed under such provisions. For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Under no circumstances will any information filed under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

    Item 8. Exhibits.

     

    Exhibit
    Number
      

    Exhibit Description

       Incorporated by Reference  

    Filed

    Herewith

       Form    Date    Number  

     

    4.1    Amended and Restated Certificate of Incorporation, as amended, currently in effect.    8-K    9/19/23    3.1  
    4.2    Bylaws, as amended, currently in effect.    8-K    9/19/23    3.2  
    4.3    Form of Common Stock Certificate.    S-1/A    9/11/23    4.2  
    5.1    Opinion of Latham & Watkins LLP.            X
    23.1    Consent of Latham & Watkins LLP (included in Exhibit 5.1).            X
    23.2    Consent of Ernst & Young LLP, independent registered public accounting firm.            X
    24.1    Power of Attorney. Reference is made to the signature page to the Registration Statement.            X
    99.1#    2023 Incentive Award Plan.    S-8    9/19/23    99.3(a)  
    99.2#    Form of Stock Option Grant Notice and Stock Option Agreement under the 2023 Incentive Award Plan.    S-1    8/25/23    10.7(b)  
    99.3#    Form of Restricted Stock Unit Award Agreement under the 2023 Incentive Award Plan.    S-1    8/25/23    10.7(c)  
    99.4#    2023 Employee Stock Purchase Plan.    S-8    9/19/23    99.4  
    107.1    Filing Fee Table.            X

     

    #

    Indicates management contract or compensatory plan.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in City of Watertown, Commonwealth of Massachusetts, on this 3rd day of March, 2025.

     

    Neumora Therapeutics, Inc.
    By:  

    /s/ Paul L. Berns

      Name: Paul L. Berns
      Title: Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Paul. L Berns and Michael Milligan, and each of them, with full power of substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file this Registration Statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature

      

    Title

      

    Date

    /s/ Paul L. Berns

    Paul L. Berns

      

    Chief Executive Officer and Chairman of the Board of Directors

    (Principal Executive Officer)

       March 3, 2025

    /s/ Michael Milligan

    Michael Milligan

      

    Chief Financial Officer and Principal Accounting Officer

    (Principal Financial Officer)

       March 3, 2025

    /s/ Kristina M. Burow

    Kristina M. Burow

       Director    March 3, 2025

    /s/ Matthew K. Fust

    Matthew Fust

       Director    March 3, 2025

    /s/ Alaa Halawa

    Alaa Halawa

       Director    March 3, 2025

    /s/ Maykin Ho

    Maykin Ho, Ph.D.

       Director    March 3, 2025

    /s/ David Piacquad

    David Piacquad

       Director    March 3, 2025
    Get the next $NMRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NMRA

    DatePrice TargetRatingAnalyst
    1/12/2026$8.00Outperform
    Leerink Partners
    12/1/2025$7.00Sector Perform → Outperform
    RBC Capital Mkts
    10/27/2025$14.00Neutral → Buy
    Guggenheim
    9/16/2025Neutral → Underweight
    Analyst
    4/2/2025$1.00Buy → Underperform
    BofA Securities
    3/10/2025Outperform → Mkt Perform
    William Blair
    3/7/2025Buy → Neutral
    Guggenheim
    3/7/2025$6.00 → $2.00Buy → Hold
    Stifel
    More analyst ratings

    $NMRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

    WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m. ET in New York, NY. A live webcast of the fireside chat will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and

    2/4/26 7:00:00 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones

    Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score Cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027 WATERTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics

    1/5/26 6:35:00 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation

    NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect  NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population with elevated anxiety NMRA-511 demonstrated a favorable tolerability and safety profile Neumora plans to evaluate higher doses of NMRA-511 via initiation of a multiple ascending dose expansion cohort in 2026 Company to host conference call today at 8:00 am ET WATERTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms

    1/5/26 6:30:00 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NMRA
    SEC Filings

    View All

    Neumora Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)

    2/11/26 7:00:26 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neumora Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)

    1/12/26 7:00:19 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Neumora Therapeutics Inc.

    8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)

    1/5/26 6:44:27 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Milligan Michael Lee

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    1/9/26 4:20:47 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Officer Aurora Daljit Singh

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    1/9/26 4:19:28 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Officer Duncan Jason

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    1/9/26 4:18:53 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NMRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Neumora Therapeutics with a new price target

    Leerink Partners initiated coverage of Neumora Therapeutics with a rating of Outperform and set a new price target of $8.00

    1/12/26 8:18:29 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neumora Therapeutics upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Neumora Therapeutics from Sector Perform to Outperform and set a new price target of $7.00

    12/1/25 8:13:43 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neumora Therapeutics upgraded by Guggenheim with a new price target

    Guggenheim upgraded Neumora Therapeutics from Neutral to Buy and set a new price target of $14.00

    10/27/25 8:50:37 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NMRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Burow Kristina bought $4,999,977 worth of shares (1,915,700 units at $2.61) (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    10/29/25 7:22:24 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Arch Venture Partners Xii, Llc bought $4,999,977 worth of shares (1,915,700 units at $2.61) (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    10/29/25 7:21:13 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Arch Venture Partners X, Llc bought $4,999,977 worth of shares (1,915,700 units at $2.61) (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    10/29/25 7:19:14 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NMRA
    Leadership Updates

    Live Leadership Updates

    View All

    Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

    On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024 Strong financial position with $463.8 million in cash, cash equivalents and marketable securities expected to support operations into 2026 WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update. "2023 was a watershed year for Neumora as we

    3/7/24 7:00:00 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer

    WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora's executive team, reporting to Henry Gosebruch, president and chief executive officer. Ms. Pai Panandiker has more than 20 years of experience commercializing medicines in areas of significant unmet need, including the commercial launches of TRINTELLIX® (vortioxetine) and REXULTI® (brexpiprazole) for major depressive disorder (MDD) and schizophrenia. "I am excited to welcome Kaya to Neumora. As we progress t

    1/22/24 7:00:00 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

    WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Jason Duncan as chief legal officer. Mr. Duncan will be a member of Neumora's Executive Team, reporting to Henry Gosebruch, chief executive officer, and will oversee all aspects of the Company's legal and compliance functions. "I am pleased to welcome Jason to Neumora. With his unique background that combines legal expertise with program strategy, I am confident that he will be a valuable addition to our team as we seek to deliver on our mission to redefine neuroscience drug dev

    12/12/23 7:00:00 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NMRA
    Financials

    Live finance-specific insights

    View All

    Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation

    NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect  NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population with elevated anxiety NMRA-511 demonstrated a favorable tolerability and safety profile Neumora plans to evaluate higher doses of NMRA-511 via initiation of a multiple ascending dose expansion cohort in 2026 Company to host conference call today at 8:00 am ET WATERTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms

    1/5/26 6:30:00 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of obesity as lead indication for NMRA-215, a highly brain-penetrant NLRP3 inhibitor, with data from diet-induced obesity (DIO) mouse model expected in 2025 Entering catalyst-rich period with up to six clinical data readouts in patients over the next 18 months, including Phase 3 data for navacaprant in major depressive disorder (MDD) and Phase 1b data for NMRA-511 in Alzheimer's disease agitation Strong financial position with $217.6 million in cash, cash equivalents

    8/6/25 4:05:00 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

    WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and provide a business update. A live webcast of the event will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 day

    7/23/25 7:00:00 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Neumora Therapeutics Inc.

    SC 13D/A - Neumora Therapeutics, Inc. (0001885522) (Subject)

    11/22/24 5:33:43 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Neumora Therapeutics Inc.

    SC 13G - Neumora Therapeutics, Inc. (0001885522) (Subject)

    11/12/24 4:30:30 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care